CliffBio
biologic

Bayrab,Hyperrab

Rabies Immune Globulin (Human)

Loss of exclusivityNovember 2031projected — 12-year biologic exclusivity estimate
CompanyGrifols →View the full company profile on CliffBio

Drug detail

Brand nameBayrab,Hyperrab
Active ingredientRabies Immune Globulin (Human)
Strength900 IU/ 3ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalNovember 2019
Marketing statusRx

More from Grifols

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bayrab,Hyperrab patent cliff — loss of exclusivity November 2031 | CliffBio